Archive | March, 2017

Healthcare IT Investors Share Their Strategies at RESI on MaRS

16 Mar

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

Healthcare IT entrepreneurs, as opposed to biotech/medtech entrepreneurs, enjoy some favorable realities when it comes to successfully launching and sustaining a new venture. However, even though software and healthcare IT companies require far less capital than a biopharmaceutical product or medical device to get up and running, investors tend to place an emphasis on market penetration and traction, often the rate limiting step for these startups. A key to overcoming this hurdle is healthy ecosystem with innovative institutions willing to put programs in place to help new digital health technologies enter the marketplace and refine their product.

Canada is embracing digital health and the impact it can have on the public, patients and the healthcare system at large. Toronto, as the epicenter of Canadian healthcare and innovation, is naturally working to catalyze venture creation in healthcare IT and will host the RESI conference and a panel of venture investors active in the space.

The session will feature the following investors:

By registering for RESI on MaRS, you’ll be able to listen to the Healthcare IT panel live, interact with the investors and experience numerous opportunities to expand your network.

Tags: , , , , ,

Hot Investor Mandate 1: Cross-Border Fund Invests in Highly Innovative Early Stage Medtech, Diagnostics and Healthcare IT

16 Mar

A VC firm with offices in California, Beijing, and Hong Kong manages over 100 portfolio companies in the US and China. The firm generally invests in the early stages, mostly in seed and Series A rounds. The firm focuses its investments in U.S. and China, but also considers companies based in Canada.

In the life sciences sector, the firm will consider medical technology, diagnostic, and healthcare IT companies. The firm is open to all types of medical technology in all types of indications, and will look at both 510k and PMA medical devices in development or clinical trials. Previously, the firm has also invested in the synthetic engineering space.

The firm is looking for early-stage companies with a highly innovative product. The management team of potential portfolio companies is expected to be committed to the company full-time and will have a track of strong, successful entrepreneurship. The firm does not require a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Seed Investment Firm Raises New Fund, Seeks Healthcare IT Opportunities

16 Mar

An early-stage seed fund based in Palo Alto, CA focuses on seed stage and sometimes Series A. Typical equity allocations range from $500 – 750 K per company. The firm is open to both leading and co-investing. The firm has been investing from a $50M fund and is currently raising a new fund, from which it expects to make new investments. The firm is seeking opportunities from across the US with a focus on the Bay Area.

The firm invests across multiple industries including healthcare IT. The firm prefers products that do not require FDA approval. Within healthcare IT, the firm considers both consumer-facing and enterprise solutions that demonstrate customer traction and large market potential.

The firm can work with incomplete management teams and would require a board seat on a case-by-case basis. The firm has funded companies in which the founders were either current students or recent graduates from top US universities

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: China-based Firm Invests in Preclinical Drugs in Oncology and Chronic Diseases

16 Mar

The biotech and healthcare subsidiary company of a large real estate corporation in China is interested in biotech technology, products and services with large potential in the Chinese market. The firm aims to launch them in China through partnership, investment and cooperation. Typical equity investments range from US$0.7-1.5 million (RMB 5-10 million), up to 3.5 million in later stage companies. The firm prefers to co-invest in a round with a strong, reputable lead. The firm considers opportunities from around the world with a focus on China, the US, and Australia.

The firm is interested in preclinical therapeutic projects in oncology, chronic diseases such as diabetes, and other disease indications with large market potential. The firm is open to all therapeutic modalities.

The firm is looking for experienced teams backed by strong lead investors. The firm may request board representation on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: New Subsidiary of Investment Firm Seeks Technology-Driven Medical Devices

16 Mar

A Chinese investment company has founded a new U.S. based subsidiary, which typically makes seed investments of US$50k-250k in technology companies. The firm is currently focused on companies based in the Cambridge, MA area, but it is also open to opportunities from across the US. The firm would prefer companies with a China angle although they are open to investing in companies with a U.S. focus.

Within healthcare, the firm is currently interested in technology-driven medical devices, robotics, and artificial intelligence. The firm is not interested in software-only products.

The firm is looking for founders with strong academic credentials and sector expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

30 Leading Life Science Startups Compete in Innovation Challenge at The Redefining Early Stage Investments (RESI) Conference at MaRS

9 Mar

By Michael Quigley, VP of Market Research, LSN

mike-2

As RESI gears up for its second landing on MaRs in Toronto this April 4th we are proud to announce our latest batch of life science/health tech companies that will be participating in the RESI Innovation Challenge.

30 companies from across North America, hand selected by LSN’s scientific and commercial review team, will compete directly on merits of innovation and commercial viability.  Past RESI events have seen as many as 50% of innovation challenge contestants go on to receive funding or significant partnerships within a year from the competition.

From companies helping to detect oncoming seizures to those developing cost effective ways of growing blood stem cells, this diverse class of competitors is sure to impress. Come check them our yourself in the Exhibition Hall at RESI on MaRs on April 4th!

Therapeutic
 
Diagnostic
Medical Device
 
Healthcare IT
 

Tags: , , , , , ,

RESI@MaRS Panel Announcement: Early Stage Therapeutic Investors

9 Mar

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

Despite therapeutic companies’ high-risk development timeline, investors continue to remain focused on investing in biotechnology, seeing its long-term impact and enormous potential in the healthcare industry. Along with the technology, entrepreneurs need to also consider capital intensity, fundraising and milestone timeline, management team, and endpoint selections, among other topics beyond the science.

LSN has assembled five active investors specifically interested in early-stage biotech therapeutics for RESI Toronto, occurring on April 4th. Held in the heart of Canada’s healthcare innovation hub, MaRS Discovery District.

The Early Stage Therapeutic Investors Panel will be moderated by Mark Day, Head, CNS Virtual Discovery of Purdue Pharma, and will be joined by:

The panel will serve as an educational opportunity for scientist entrepreneurs to better understand the investment trends; the investor’s perspective when approaching a deal in a high-risk space; and note-worthy advice to entrepreneurs on the best way to approach and work with investors such as themselves.09

This is a tremendous opportunity for biotech life science entrepreneurs and investors to meet and develop relationships in person. Register for RESI@MaRS now so you don’t miss the chance.

Tags: , , , , , ,

← Older Entries
Newer Entries →